ライフサイエンスコーパス: galectin 3

1 erminal pro-B-type natriuretic peptide], and galectin-3).

2 ore 2 structures did not bind to recombinant galectin-3.

3 y mediating interaction between lubricin and galectin-3.

4 ors become upregulated, including the lectin galectin-3.

5 thelial cell surfaces treated with exogenous galectin-3.

6 in fibrotic areas contained large amounts of galectin-3.

7 NKp30 blocking Ab and an inhibitory ligand, galectin-3.

8 functional beta-galactoside-binding protein, galectin-3.

9 are positive for the membrane damage marker Galectin-3.

10 homonas depleted the extracellular levels of galectin-3.

11 s against FcepsilonRI, FcepsilonRII/CD23 and galectin-3.

12 liver production of the profibrotic lectin, galectin-3.

13 factor, transforming growth factor beta, and galectin-3.

14 lectin-1, -3, -8, confirming selectivity for galectin-3.

15 luble form of ST2 (33 [24.6-48.1] ng/mL) and galectin 3 (17.8 [14.1-22.8] ng/mL) were higher, and for

16 Colocalization of alphaS pathology with galectin-3 (a marker of endo-lysosomal membrane rupture)

17 We hypothesized that human galectin-3, a beta-galactoside-binding lectin involved i

18 f more highly sulfated C4S, which binds less galectin-3, a beta-galactoside-binding protein.

19 Galectin-3, a carbohydrate-binding protein with affinity

20 the staphylococcal protease SspB inactivates galectin-3, abrogating its stimulation of oxygen radical

21 These results show that galectin-3 acts as a pro-invasive autocrine/paracrine fa

22 Using two different galectin-3 affinity purification processes, we extracted

23 lso observed colocalization between YopD and Galectin-3, an indicator of endosomal membrane damage.

24 is was characterized by marked expression of galectin-3 and an enhanced number of proliferating RV fi

25 onic anhydrase-12, and NC markers brachyury, galectin-3 and CD24 in cells of the NP irrespective of a

26 ges, including fractional area of liver fat, galectin-3 and Col1a1.

27 Soluble recombinant galectin-3 and endogenous galectin-3 of epithelial origi

28 alidated CaRe by purifying recombinant human galectin-3 and five other known lectins and also tested

29 Galectin-3 and galectin-1, binding partners of LGALS3BP,

30 in promoting MUC16's binding affinity toward galectin-3 and in causing retention of the lectin on the

31 The relative expression of galectin-3 and matrix metalloproteinase 9 (MMP9) was eva

32 The impact of galectin-3 and protease expression on S. aureus virulenc

33 Both the level of galectin-3 and the galectin-3 interactions with synovial

34 us approximately 10S particle that contained galectin-3 and U1 snRNP and this particle was sufficient

35 (macrophage surface glycoproteins binding to galectin-3) and an increase of renal epithelial damage m

36 (the human adhesion/growth-regulatory lectin galectin-3) and its consequences in structural terms wer

37 5 (growth differentiation factor 15), GAL-3 (galectin-3), and Cys-C (cystatin-C) were assessed before

38 neutrophil gelatinase-associated lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase

39 ammation and caused up-regulation of Cxcl16, Galectin-3, and Nedd9, among others.

40 brogated by bacterium-derived proteolysis of galectin-3, and SspB was identified as the major proteas

41 lomerular filtration rate, creatinine, NGAL, galectin-3, and urea.

42 overall showed smaller lesion sizes than the galectin-3(+/+) animals.

43 nti-fibronectin antibody and beta-lactose, a galectin-3 antagonist, significantly blocked DC exosome-

44 ions 3-5) of the glycerol gradient with anti-galectin-3 antibodies.

45 In conclusion, elevated levels of plasma galectin-3 are associated with increased risks of rapid

46 The role of galectin-3 as a modulator of inflammation has been studi

47 Conclusions: We identified extrapulmonary galectin-3 as an important mediator that drives RV fibro

48 These findings suggest LGALS3BP and galectin-3 as new targets to treat metastatic cancer and

49 -based gene knockout approach, we identified galectin-3 as the major counterreceptor of GPVI on tumor

50 the self-association-related multivalency of galectin-3 at the residue-specific level.

51 IgG(4) galectin-3 autoantibodies are present in a subset of pat

52 IgG(4) anti-galectin-3 autoantibodies correlated with increased plas

53 Anti-galectin-3 autoantibody responses were predominantly of

54 rn blot, an intact ( approximately 28.0 kDa) galectin-3 band was identified in tear samples from heal

55 Galectin-3 binding protein (Gal-3BP) is a large hypergly

56 Purification indicated that Galectin-3 binding protein (LGALS3BP) is the active fact

57 Galectin-3 binding protein could be considered as potent

58 ucin-type O-glycoprotein displayed increased galectin-3 binding.

59 CD146 was the major galectin-3-binding ligand and strongly co-localized with

60 Thus, CD146/MCAM is the functional galectin-3-binding ligand on endothelial cell surfaces r

61 Here we sought to identify the galectin-3-binding molecule(s) on the endothelial cell s

62 Galectin-3-binding protein (gal3bp) and its receptor/lig

63 chymotrypsin, ficolin-2, 14-3-3 protein, and galectin-3-binding protein were considered potential bio

64 roteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-binding protein) improved risk prediction and

65 00A8), S100A9, cathepsin B, fibronectin, and galectin-3-binding protein.

66 Moreover, galectin-3 bound to N-linked glycans on CD146 and induce

67 chomonas CPI-GC that had reduced affinity to galectin-3 but maintained affinity to galectin-1 suppres

68 uctures; the MDA-MB-231 cells had no surface galectin-3 but used surface galectin-1 for interaction w

69 lectin-3 inhibition, showed no inhibition of galectin-3 by the polysaccharides.

70 d phase separation, and we demonstrated that galectin-3 can also undergo liquid-liquid phase separati

71 We report that galectin-3 can bind to TLR-4, and that administration of

72 Uric acid, C-reactive protein, galectin-3, carboxy-terminal telopeptide of collagen typ

73 This correspondence is a reply to Galectin-3, Cardiac Function, and Fibrosis by Wouter C.

74 activating polypeptide II, ectodysplasin A2, Galectin-3, chemokine (C-X-C motif) ligand 2, Nidogen1,

75 hree subtype galectins, galectin-2 (proto-), galectin-3 (chimera-) and galectin-4 (tandem repeat-type

76 In addition, galectin-3 colocalized predominantly with the HPS-5 comp

77 In the cell body, galectin-3 colocalizes with melanosome-destined cargo, s

78 Galectin-3 concentration was significantly associated wi

79 Per SD increase in log-transformed galectin-3 concentration, the risks of all-cause mortali

80 We measured galectin-3 concentrations in baseline samples from the G

81 In conclusion, galectin-3 concentrations increased with progressive ren

82 Mean+/-SD galectin-3 concentrations were 12.8+/-4.0 ng/ml (eGFR>/=

83 We correlated galectin-3 concentrations with demographic, clinical, an

84 Galectin-3 content in tears was analyzed by quantitative

85 nt interactions of transmembrane mucins with galectin-3 contribute to maintenance of the epithelial b

86 Galectin-3 correlated significantly with certain biomark

87 dimer, fibrinogen, C-reactive protein, sST2, galectin-3, cystatin-C, and urinary albumin-to-creatinin

88 istration of a neutralizing antibody against galectin-3 decreases the expression of IL-1beta, IL-6, T

89 anti-inflammatory properties by assembling a galectin-3-Dectin-1-FcgammaRIIB receptor complex that ac

90 uoles or YCVs is substantially diminished in Galectin-3-deficient cells.

91 Moreover, corneas of galectin-3-deficient mice failed to stimulate IL-1beta a

92 of the impaired immune response observed in galectin-3-deficient mice in vivo.

93 ce of proteases other than MMPs in promoting galectin-3 degradation in dry eye.

94 ns and clinical isolates of S. aureus caused galectin-3 degradation.

95 Molecular mechanisms underlying galectin-3-dependent inflammatory responses were further

96 cretion systems into PV membranes stimulates Galectin-3-dependent recruitment of antimicrobial GBPs t

97 nhibition in NSCLC, we tested the effects of galectin-3 depletion using genetic and pharmacologic app

98 vidence for the hypothesis that chimera-type galectin-3 design makes functional antagonism possible,

99 tic liver injury, we generated dnTGF-betaRII/galectin-3(-/-) (dn/Gal3(-/-)) mice, which showed impair

100 Taking all together, galectin-3 emerges as a clinically relevant target for T

101 This suggests that in response to EGF, galectin-3 enables outside-in integrin signaling stimula

102 artilage surface, and addition of multimeric galectin-3 enhances cartilage lubrication.

103 tion of galectin-3 protein in tears, but not galectin-3 expression in conjunctival epithelium, was si

104 studies concerning clinical implications of galectin-3 expression in patients with acute myeloid leu

105 We found that galectin-3 expression mimicked the defective expression

106 use model of transverse aortic constriction, galectin-3 expression was markedly up-regulated in the p

107 No changes of galectin-3 expression were observed in the lungs.

108 leomorphism, fibrous septation and increased galectin-3 expression, consistent with atypical parathyr

109 MP)-1 and -2 and also increased collagen and galectin-3 expression.

110 tion to isolated hepatic macrophages reduced galectin-3 expression.

111 vity troponin I (hsTnI), soluble (s)ST2, and galectin-3 from baseline to 26, 52, and 104 weeks.

112 ed with the ability of active MMP9 to cleave galectin-3 from recombinant origin.

113 Galectin-3 (Gal-3) can cross-link surface glycoproteins

114 ing were used to investigate the function of galectin-3 (Gal-3) during the process of leukocyte recru

115 Galectin-3 (Gal-3) has been linked to cardiac remodeling

116 We studied the role of galectin-3 (Gal-3) in the expression of alternative acti

117 Galectin-3 (Gal-3) is a carbohydrate binding lectin, wit

118 Galectin-3 (gal-3) is expressed in well-differentiated a

119 Galectin-3 (Gal-3) is implicated in cardiac fibrosis, bu

120 Mammalian beta-galactoside-binding protein Galectin-3 (Gal-3) modulates the host innate and adaptiv

121 ST2 and galectin-3 (Gal-3) were compared head-to-head for long-t

122 nflammation markers soluble (s)CD163, sCD14, galectin-3 (Gal-3), and Gal-3 binding protein (Gal-3BP)

123 At inclusion, Galectin-3 (Gal-3), N-terminal proB-type natriuretic pep

124 -1, matrix metalloproteinase (MMP)-2, MMP-9, Galectin-3 (Gal-3), N-terminal propeptide of collagen I

125 ion of the beta-galactoside binding protein, Galectin-3 (Gal-3).

126 n/growth-regulatory galectins, in particular galectin-3 (Gal-3).

127 hree different endocytic ligands-folic acid, galectin-3 (Gal3) and the Shiga toxin B-subunit (STxB).

128 We studied the role of galectin-3 (Gal3) in gastric infection by Helicobacter p

129 Here, we show that galectin-3 (Gal3), a beta-galactoside-binding cytosolic

130 Galectin-3 (Gal3), a lectin mainly secreted by macrophag

131 Galectin-3 (Gal3), a pleiotropic lectin, is produced by

132 ng protein (gal3bp) and its receptor/ligand, galectin-3 (gal3), are secreted proteins that initiate s

133 In further studies, we focused on galectin-3 (Gal3), identified in this study as a negativ

134 ial cells identified a lectin referred to as galectin-3 (Gal3).

135 We also characterise a subpopulation of galectin-3(+) (Gal3(+)) myeloid cells within the develop

136 tandem repeats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA pr

137 Galectin-3 genetic and pharmacologic inhibition or antif

138 bitor, which strongly suggests that blocking galectin-3 glycan recognition is an important antifibrot

139 33 ng/mL soluble form of ST2 and <17.8 ng/mL galectin 3) had reduction in left atrial volume, those a

140 Galectin-3 has an intrinsically disordered N-terminal do

141 Galectin-3 has been implicated in a broad range of biolo

142 Galectin-3 has been linked to incident renal disease, ex

143 We also find that galectin-3 has low affinity for the surface layer of ost

144 Increased levels of galectin 3 have been associated with nonalcoholic steato

145 Mice deficient for galectin-3 have elevated blood parasitemia levels and im

146 the requisite glycan epitopes needed to bind galectin-3 have long been elucidated, the cellular glyco

147 and clinical use of repeated measurements of galectin-3 have not yet been reported.

148 etween a C-terminal domain fragment of human galectin-3 (hGal-3C) and three human serum GPs, alpha-1-

149 id intima-media thickness, apolipoprotein B, galectin-3, high-sensitivity C-reactive protein, lipopro

150 ect activation of integrin with Mn2+ induces galectin-3, ILK, and Src-dependent RhoA activation and c

151 (hematoxylin-eosin staining), inflammation (galectin-3 immunohistochemistry (IHC); gal-3), and fibro

152 In contrast, parallel anti-galectin-3 immunoprecipitation of free galectin-3 molecu

153 f perfluorcarbon-labeled immune cells, Mac-2/Galectin-3 immunostaining, and FACS (fluorescence-activa

154 ain of L. major, LV39, was infected, lack of galectin-3 impaired neutrophil recruitment in the footpa

155 One specific TRIM, TRIM16, interacted with Galectin-3 in a ULK1-dependent manner.

156 y aimed to investigate the potential role of galectin-3 in cell migration and invasion, using recombi

157 We investigated the potential function of galectin-3 in cell-mediated immunity using peripheral bl

158 Downregulation of galectin-3 in human melanocytes using short hairpin RNA

159 the glycan and glycoprotein interactors for galectin-3 in live human hepatic stellate cells and peri

160 e show a large increase in the expression of galectin-3 in microglia and also an increase in the rele

161 In this study, we investigated the role of galectin-3 in neutrophil migration and the biological si

162 We investigated the role of galectin-3 in systemic and local responses in a murine m

163 The cooperation between TRIM16 and Galectin-3 in targeting and activation of selective auto

164 Interestingly, cleavage of endogenous galectin-3 in tear samples was impaired using a broad-sp

165 esis, cultured fibroblasts were treated with galectin-3 in the absence or presence of galectin-3 inhi

166 and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after h

167 mes detected the presence of fibronectin and galectin-3 in those derived from DCs, whereas T-cell exo

168 Nuclear galectin-3 increased and mediated increased binding of S

169 Silencing of galectin-3 induced significant reduction in cell migrati

170 ates but not in Staphylococcus saprophyticus Galectin-3-induced activation of the neutrophil NADPH ox

171 of CD146 expression completely abolished the galectin-3-induced secretion of IL-6 and G-CSF cytokines

172 on endothelial cell surfaces responsible for galectin-3-induced secretion of metastasis-promoting cyt

173 To examine the role of galectin-3 inhibition in NSCLC, we tested the effects of

174 To elucidate the beneficial effects of galectin-3 inhibition on myocardial fibrogenesis, cultur

175 sing cell-based assays, indirectly linked to galectin-3 inhibition, showed no inhibition of galectin-

176 ral administration of a novel small molecule galectin-3 inhibitor GB1107 reduced human and mouse lung

177 The efficacy of the galectin-3 inhibitor N-acetyllactosamine was evaluated i

178 The novel galectin-3 inhibitor presented could provide an effectiv

179 r to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests that block

180 ith galectin-3 in the absence or presence of galectin-3 inhibitor.

181 In this work, two galectin-3 inhibitors were radiolabeled with fluorine-18

182 sulted in highly selective and high affinity galectin-3 inhibitors.

183 ctively reacted to give rise to a library of galectin-3 inhibitors.

184 actions was further validated by analysis of galectin-3 interaction with a semisynthetic ligand, F3.

185 ore 2 O-linked glycans mediate this lubricin-galectin-3 interaction, shown by surface plasmon resonan

186 Both the level of galectin-3 and the galectin-3 interactions with synovial lubricin were foun

187 ur results indicate that release of cellular galectin-3 into tears is associated with epithelial dysf

188 Galectin-3 is a beta-galactoside-binding lectin that is

189 Galectin-3 is a family member of the carbohydrate-bindin

190 Galectin-3 is a glycan-binding protein (GBP) that binds

191 for these proteases and that proteolysis of galectin-3 is a novel immune evasion mechanism.

192 These data indicate that galectin-3 is a regulatory component in melanin synthesi

193 bers present in synovial fluid, we find that galectin-3 is a specific, high-affinity binding partner

194 Galectin-3 is an active biomarker found in inflammatory

195 In summary, galectin-3 is an important regulator of lung adenocarcin

196 We find that galectin-3 is broadly up-regulated in KLF3-deficient mou

197 how expression of the inflammatory modulator galectin-3 is controlled, opening up avenues for potenti

198 The galactoside-binding protein galectin-3 is increasingly recognized as an important pl

199 enabling multivalency for various functions, galectin-3 is monomeric, and its functional multivalency

200 ts potential role as a prognostic biomarker, galectin-3 is not a critical modulator of cardiac fibros

201 The beta-galactoside-binding animal lectin galectin-3 is predominantly expressed by activated macro

202 Using novel co-culture model systems, galectin-3 is shown to facilitate basophil secretion of

203 These results suggest that galectin-3 is strongly involved in Chagas disease, not o

204 The beta-galactoside-binding protein galectin-3 is widely expressed in well-differentiated th

205 Galectin-3 knock-out and wild-type mice were subjected t

206 europrotection in the cortical region in the galectin-3 knockout animals in response to TBI.

207 Galectin-3 knockout mice exhibited accelerated cardiac h

208 chocardiographic assessment was performed on galectin-3 knockout or inhibitor-treated mice.

209 7 days of pressure overload, whereas female galectin-3 knockouts had delayed dilation after 28 days

210 oantibodies correlated with increased plasma galectin-3 levels (P = .001), lymphadenopathy (P = .04),

211 The impact of changing galectin-3 levels on other secondary end points was comp

212 Galectin-3 levels were elevated in 22 patients (22%) at

213 Despite considerable interest in galectin-3, little is known about its physiological regu

214 t cardiomyocyte- but not macrophage-specific galectin-3 localization was associated with adverse remo

215 However, galectin-3 loss did not affect survival, systolic and di

216 ovascular disease, respectively, followed by galectin-3 <25th percentile (DLR 0.44 and 0.43, respecti

217 I 0.23) and CAC <=10 (NRI 0.28), followed by galectin-3 <25th percentile (NRI 0.14) and absence of ca

218 by a failure of numerous PSCs to upregulate galectin-3 (MAC-2), a marker of glial axonal debris phag

219 2 (an interleukin-1 receptor family member), galectin-3, matrix metalloproteinase-2, and collagen III

220 We propose that galectin-3 may achieve multivalency through this multisi

221 suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other p

222 We hypothesized that galectin-3 may be up-regulated in the pressure-overloade

223 hat CD146/MCAM interactions with circulating galectin-3 may have an important influence on cancer pro

224 d develop selective therapeutics to mitigate galectin-3-mediated biological events.

225 endothelial cell surface responsible for the galectin-3-mediated cytokine secretion.

226 In galectin-3(+/+) mice, SspB-expressing S. aureus caused l

227 Galectin-3(-/-) mice developed significantly smaller and

228 ositive bone marrow restored tumor growth in galectin-3(-/-) mice, indicating that macrophages were a

229 acterial load or lesion size was detected in galectin-3(-/-) mice, which overall showed smaller lesio

230 tumorgenicity 2, highly sensitive troponin, galectin-3, midregional proadrenomedullin, cystatin-C, i

231 Serum galectin-3 modestly increased from baseline with canagli

232 anti-galectin-3 immunoprecipitation of free galectin-3 molecules not in a complex with U1 snRNP (fra

233 oluble recombinant galectin-3 and endogenous galectin-3 of epithelial origin both stimulated MMP9 act

234 inding ligand and strongly co-localized with galectin-3 on endothelial cell surfaces treated with exo

235 Removal of galectin-3, one of basal-body components, provokes misre

236 ex and that U1 snRNP is required to assemble galectin-3 onto an active spliceosome.

237 th inhibitors of scavenger receptor class B, galectin-3, or blocking antibodies against CD36, suggest

238 erly individuals with CAC = 0, CAC <=10, low galectin-3, or no carotid plaque had remarkable low card

239 by baseline level of soluble form of ST2 and galectin 3; patients with values less than the observed

240 f patients with IgG(4)-RD and correlate with galectin-3 plasma levels.

241 We conclude that galectin-3 plays a crucial role in the maintenance of th

242 ed tumor growth, whereas reconstitution with galectin-3-positive bone marrow restored tumor growth in

243 ds its cognate elements (CACCC boxes) in the galectin-3 promoter and represses its activation in cell

244 Remarkably, galectin-3 promotes cellular infiltration in the heart o

245 The concentration of galectin-3 protein in tears, but not galectin-3 expressi

246 quantitative Western blot, using recombinant galectin-3 protein to generate a calibration curve.

247 atment with galectin-3 siRNA both LGALS3 and galectin-3 protein were dramatically decreased.

248 epithelial dysfunction in dry eye, and that galectin-3 proteolytic cleavage may contribute to impair

249 on of membrane-damage signals as detected by galectin-3 recruitment.

250 In contrast, silencing galectin-3 reduced IL-8 response to LPG.

251 Galectin-3 regulates inflammasome activation in cholesta

252 Galectin-3 regulates inflammatory and fibrotic responses

253 Together, our results suggest that galectin-3 reinforces the lubricin boundary layer; which

254 However, the association among galectin-3, renal function, and adverse outcomes has not

255 ration and invasion, using recombinant human galectin-3 (rhgalectin-3), small molecule galectin inhib

256 Galectin-3 silencing inhibited the ARSB-silencing-induce

257 small molecule galectin inhibitor I(47), and galectin-3 silencing.

258 Upon HTR-8/SVneo cell treatment with galectin-3 siRNA both LGALS3 and galectin-3 protein were

259 ats (VNTRs) that bind the lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1

260 e B activity, with subsequent impact on C4S, galectin-3, Sp1, and Wnt9A and can exert significant eff

261 his study reviews several novel biomarkers - galectin-3, ST2 and copeptin.

262 trated that the carbohydrate-binding protein galectin-3 stimulated microenvironment remodeling in the

263 In vitro, cytokine stimulation suppressed galectin-3 synthesis by macrophages and cardiac fibrobla

264 of antibody showed much higher affinity for galectin-3 than that of the commercial antibody.

265 GR-MD-02 (belapectin) is an inhibitor of galectin 3 that reduces liver fibrosis and portal hypert

266 ersican promoter activity increased, and the galectin-3 that co-immunoprecipitated with C4S declined.

267 mple of homodimeric galectin-1 and monomeric galectin-3, the mutual design conversion caused qualitat

268 s in biomarkers of immunity (S100A8, S100A9, galectin-3), tissue injury and repair (Serpine1/PAI-1) a

269 Considering the known ability of galectin-3 to crosslink glycoproteins, we hypothesized t

270 , these results indicate that HSV-1 exploits galectin-3 to enhance virus attachment to host cells and

271 rects cytosolic carbohydrate-binding protein Galectin-3 to PVs and that the delivery of GBP1 and GBP2

272 ppel-like factor 3 (KLF3) directly represses galectin-3 transcription.

273 w document that this interaction between the galectin-3-U1 snRNP particle and the pre-mRNA results in

274 depleted extract can be reconstituted by the galectin-3-U1 snRNP particle, isolated by immunoprecipit

275 These results indicate that the galectin-3-U1 snRNP-pre-mRNA ternary complex is a functi

276 tween platelet GPVI and tumor cell-expressed galectin-3 uses ITAM-signaling components in platelets a

277 ty to the carbohydrate recognition domain of galectin-3, using a combination of isothermal titration

278 In dialysis patients, galectin-3 was associated with the combined end point of

279 In normal mouse myocardium, galectin-3 was constitutively expressed in macrophages a

280 Galectin-3 was identified as the antigen specifically re

281 Galectin-3 was increased in TSC-related skin tumors, ang

282 Signature component Lgals3 encoding galectin-3 was increased in Tsc2-deficient cells and ser

283 Early up-regulation of galectin-3 was localized in subpopulations of macrophage

284 When galectin-3 was silenced, the increases in Sp1 binding to

285 e activated, and secretion of the Mer ligand Galectin-3 was stimulated.

286 The cleavage of galectin-3 was studied in vitro using activated recombin

287 Serum levels of galectin-3 were increased in patients with idiopathic pu

288 ng affinities to peanut agglutinin and human galectin-3 were measured by isothermal titration calorim

289 growth factor-binding protein-7], and GAL-3 [galectin-3]) were assessed.

290 rms a lattice with the N-glycan of TRPV5 via galectin-3, which impairs TRPV5 endocytosis and increase

291 We have shown previously that circulating galectin-3, which is increased up to 30-fold in cancer p

292 We demonstrate that melanocytes express galectin-3, which is predominantly localized to the cell

293 The method employs a (89)Zr-labeled mAb to galectin-3, which shows high specificity and binding aff

294 erived from IGHV4-34 using PCNSL, recognized galectin-3, which was upregulated on microglia/macrophag

295 The association of galectin-3 with clinical end points was assessed by Cox

296 sion models to evaluate associations between galectin-3 with incident renal outcomes at examination 8

297 ic peptides, adrenomedullin, endothelin, and galectin-3 with new-onset HF was stronger in the high-ri

298 These data demonstrate an association of galectin-3 with unfavorable host response in leprosy and

299 is partly attributable to the interaction of galectin-3 with unknown receptor(s) on vascular endothel

300 iguingly, YopK limited the colocalization of Galectin-3 with YopD, suggesting that YopK limits the in